Nabumetone kinetics in the young and elderly

Area of Science:

• Pharmacokinetics
• Geriatric Medicine
• Drug Metabolism

Background:

• Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) from the naphthylalkanone class.
• NSAIDs are commonly used for degenerative joint disease.

Purpose of the Study:

• To compare the single-dose and steady-state pharmacokinetics of nabumetone in young healthy males and elderly patients.
• To determine if nabumetone accumulates with daily dosing.
• To assess potential dose adjustments for elderly populations.

Main Methods:

• Open-label study comparing young (21-30 years) and elderly (60-75 years) participants.
• Single oral dose (1,000 mg) and 14-day daily dosing (1,000 mg) of nabumetone.
• Blood and urine samples collected over five days post-dose for metabolite analysis.
• Data analyzed using a single compartment model.

Main Results:

• Elderly patients showed higher plasma concentrations and longer elimination half-lives compared to young volunteers.
• Nabumetone accumulation ratio was 1.6 in young and 1.8 in elderly individuals.
• Side effects were generally mild, with headaches being common in both groups.

Conclusions:

• Nabumetone does not appear to accumulate significantly with 24-hour dosing, supporting a single daily dose regimen.
• Elderly patients may require a lower dose of nabumetone due to altered drug elimination kinetics.
• No significant changes in blood counts, chemistries, or urinalysis were observed.